filmov
tv
discovery of NX-2127, a BTK degrader for B-cell malignancies
Показать описание
link to J. Med. Chem. article:
This video describes the discovery of NX-2127, a degrader of Bruton's tyrosine kinase (BTK) for the treatment of certain B-cell malignancies. The content of this video was reported by scientists of Nurix Therapeutics in San Francisco, CA as a Drug Annotation article in the Journal of Medicinal Chemistry. The discovery project started with an advanced compound from previous research - NRX-0492. NRX-0492 showed promising efficacy, but its distribution properties complicated preclinical safety studies. Optimization of distribution by reducing molecular weight resulting in a compound (NX-2127) with improved absorption. In vivo efficacy studies established the ability of NX-2127 to cause BTK degradation through the ubiquitin proteasome system. NX-2127 also causes degradation of IKZF1 and IKVF3, two transcription factors, with likely immunomodulatory benefits. In a mouse xenograft study, NX-2127 reduced tumor growth in both wildtype and mutant tumors. Compound NX-2127 in currently in phase I clinical trials.
This video was created for academic purposes. The creator of the video has no financial stake in the sponsor of the research described in this video.
This video describes the discovery of NX-2127, a degrader of Bruton's tyrosine kinase (BTK) for the treatment of certain B-cell malignancies. The content of this video was reported by scientists of Nurix Therapeutics in San Francisco, CA as a Drug Annotation article in the Journal of Medicinal Chemistry. The discovery project started with an advanced compound from previous research - NRX-0492. NRX-0492 showed promising efficacy, but its distribution properties complicated preclinical safety studies. Optimization of distribution by reducing molecular weight resulting in a compound (NX-2127) with improved absorption. In vivo efficacy studies established the ability of NX-2127 to cause BTK degradation through the ubiquitin proteasome system. NX-2127 also causes degradation of IKZF1 and IKVF3, two transcription factors, with likely immunomodulatory benefits. In a mouse xenograft study, NX-2127 reduced tumor growth in both wildtype and mutant tumors. Compound NX-2127 in currently in phase I clinical trials.
This video was created for academic purposes. The creator of the video has no financial stake in the sponsor of the research described in this video.
0:16:22
discovery of NX-2127, a BTK degrader for B-cell malignancies
0:12:22
Safety of BTK Degrader NX-2127 for B Cell Malignancies - Dr. Alexey Danilov ASH 2023
0:02:05
Evaluating two novel BTK degraders, NX-2127 and NX-5948, in CLL
0:02:30
First-in-human trial of NX-2127 in patients with R/R B-cell malignancies
0:09:25
BTK Degraders and T Cell Function - Dr. Alexey Danilov
0:05:25
BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024
0:03:19
Insights into the activity of NX-2127 in patients with R/R B-cell malignancies
0:01:27
Safety and efficacy of NX-2127 in R/R CLL: a Phase I study
0:09:39
A deep dive into BTK degraders for the treatment of CLL
0:01:51
BTK degraders for CLL: agents that are currently in development
0:04:47
BTK degradation as a novel therapeutic strategy for relapsed CNS lymphoma
0:03:09
BTK degraders in CLL: mechanism of action, patient responses, and a look to the future
0:11:13
New Way to Block the BTK Pathway with Protein Degraders in CLL - Dr. Adrian Wiestner ASH 2022
0:04:04
Justin Taylor, MD, on Overcoming BTK-Resistant Mutations in CLL
1:11:11
CLL in 2024 : what is the unmet medical need?
0:59:54
Relapsed/Refractory CLL Treatment Options
0:02:36
Novel non-immunological agents currently under investigation for CLL
0:02:12
CAR-T therapy vs BTK inhibitors in CLL treatment
0:01:29
Combining ibrutinib with CAR-T cells: a promising therapeutic strategy in CLL
0:03:03
The evolution of treatment patterns and prognostic biomarkers in Latin American CLL patients
0:01:11
Challenges that have been faced with developing CAR-T products for CLL and future outlooks
0:25:28
Kronik Lenfositer Lösemide Nüks/Dirençli Hastalığın Tedavisi - Nilgün Sayınalp
0:01:55
Umbralisib and ublituximab in patients with CLL and comorbidities
0:48:43
Taking the Next Steps With Next-Generation BTKi in CLL, MCL, and DLBCL
Комментарии